Silexion TherapeuticsSLXN
13F holders, Q4 2025 (December 31)6holders +2
2new positions
0sold out
1famous investor
$1.92avg. 13F price*
At the end of Q4 2025, 6 institutions reported holding Silexion Therapeutics Corp. (SLXN) in their 13F filings, up 2 from Q3 2025. 2 opened new positions and 0 sold out. The largest holders were Citadel Advisors ($23K), Montag A & Associates Inc. ($6K) and UBS Group AG ($3K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Silexion Therapeutics Corp.
- CUSIP
- G1281K130
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $23K |
| Exits | 0 | $0 |
All 13F filers, Q3 2025 → Q4 2025: 13,230 shares bought, net +13,230 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| Citadel Advisors | 0.00% | New | 12,205 | $23K |
| Montag A & Associates Inc. | 0.00% | No change | 3,000 | $6K |
| UBS Group AG | 0.00% | Add +144.4% | 1,691 | $3K |
| SBI Securities Co., Ltd. | 0.00% | No change | 1,060 | $2K |
| Pflug Koory, LLC | 0.00% | No change | 333 | $639 |
| Jones Financial Companies LLLP | 0.00% | New | 26 | $50 |
"% of holder's portfolio" is SLXN's weight in each manager's 13F, not the share of Silexion Therapeutics Corp. the manager owns.